Comparison · NCT02248480-sae
Duloxetine vs Placebo: serious adverse events
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. Duloxetine vs Placebo: serious adverse events. Trial comparisons, record NCT02248480-sae. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT02248480-sae
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0.00562 | 0.000992 | 0.0311 | wilson | |
| Risk in group 2 | 0.00568 | 0.001 | 0.0315 | wilson | |
| Risk difference, group 1 minus group 2 | -0.0000638 | -0.0263 | 0.0259 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | 0.989 | 0.0623 | 15.7 | log | |
| Odds ratio, group 1 over group 2 | 0.989 | 0.0614 | 15.9 | log | |
| Number needed to treat, for one fewer participant with a serious adverse event on Duloxetine than on Placebo | 15,700 | from the risk difference interval | the interval includes no difference |
Source ClinicalTrials.gov
Groups2
Group 2 names the comparator: placebo.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | Duloxetine | Duloxetine 20 milligram (mg) for first week, 40 mg for second week and 60 mg for next 12 weeks administered orally once daily. Tapering week doses of 40 mg for three days and 20 mg for four days. | 1 | 178 | EG000 |
| Group 2 | Placebo | Placebo administered orally once a day for 15 weeks. | 1 | 176 | EG001 |
Source ClinicalTrials.gov
Harm
- What it counts
- Total, serious adverse events
- Time frame
Source ClinicalTrials.gov
Trial
- Title
- A Study of Duloxetine (LY248686) in Participants With Chronic Osteoarthritis and Knee Pain in Japan
- NCT number
- NCT02248480
- Phases
- PHASE3
- Conditions
- Osteoarthritis of the Knee
- Interventions
- Duloxetine, Placebo
- Lead sponsor
- Eli Lilly and Company
- Results first posted
- 2017-01-16
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT02248480?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT02248480-sae